Unique ID issued by UMIN | UMIN000034391 |
---|---|
Receipt number | R000039205 |
Scientific Title | Investigation for the effects of Olive leaf on human health in cross-over study. |
Date of disclosure of the study information | 2019/03/31 |
Last modified on | 2019/04/26 13:53:53 |
Investigation for the effects of Olive leaf on human health in cross-over study.
Investigation for the effects of Olive leaf on human health.
Investigation for the effects of Olive leaf on human health in cross-over study.
Investigation for the effects of Olive leaf on human health.
Japan |
Healthy adults
Adult |
Others
NO
Administration of the anti-fatigue effects of Olive leaf.
Efficacy
Changes in oxidation stress and antioxidant activity after the administration for 4weeks
Subjective fatigue sensation
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
NO
Institution is not considered as adjustment factor.
YES
No need to know
2
Prevention
Food |
Administration of test foods for 4 weeks. / Wash out for 4 weeks. / Administration of placebo foods for 4 weeks.
Administration of placebo foods for 4 weeks. / Wash out for 4 weeks. / Administration of test foods for 4 weeks.
20 | years-old | <= |
60 | years-old | > |
Male and Female
1.Healthy persons who are aged from 20 to 59 years.
1.Persons who are in treatment.
2.Persons who have medical history of cardiovascular disease.
3.Persons who have dysfunction of autonomic nervous system.
4.Persons who have medical history of nervous system disease such as unconsciousness, coma, convulsion, etc.
5.Persons who have insomnia.
6.Persons who have food allergy.
7.Persons who are heavy user of alcohol.
8.Persons whose body mass index is less than 17 and more than 31.
9.Persons who are on a diet.
10.Pregnant women.
11.Persons who usually take in olive-related food.
12.Persons who have past or current medical history of serious disease such as diabetes mellitus, hepatic disease, kidney disease, cardiac disease, cholelithiasis, etc.
13.Persons who are now participating in other clinical trials, or participated in other clinical trials within a month before obtaining his/her informed consent in this trial.
14.Persons who are judged not suitable to participate in this trial by investigators.
40
1st name | Shinichiro |
Middle name | |
Last name | Miyake |
Miyake Medical Institute Group
Representative Director
760-0017
1-10-16 Banchou,Takamatsu,Kagawa 760-0017,Japan
087-831-2101
shin@miyake.or.jp
1st name | Kei |
Middle name | |
Last name | Mizuno |
RIKEN Center for Biosystems Dynamics Research
Laboratory for Pathophysiological and Health Science
650-0047
6-7-1 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, JAPAN
078-569-8868
keimizuno@riken.jp
Miyake Medical Institute Group
Kagawa Prefecture
Local Government
RIKEN Center for Biosystems Dynamics Research
Miyake Medical Institute Group
1-10-16 Banchou,Takamatsu,Kagawa 760-0017,Japan
miyazaki@miyake.or.jp
087-831-2101
NO
一般財団法人 三宅医学研究所(香川県)
2019 | Year | 03 | Month | 31 | Day |
Unpublished
40
Completed
2018 | Year | 09 | Month | 19 | Day |
2018 | Year | 09 | Month | 19 | Day |
2018 | Year | 10 | Month | 15 | Day |
2019 | Year | 01 | Month | 11 | Day |
2018 | Year | 10 | Month | 05 | Day |
2019 | Year | 04 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039205